Antisense Oligonucleotides Market
Number of pages: 100 | Report Format: PDF | Published date: March 06, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 1.91 billion |
|
Revenue Forecast in 2031 |
US$ 4.61 billion |
|
CAGR |
10.25% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Years |
2021 |
|
Segments Covered |
Drug, Indications, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global antisense oligonucleotides market was valued at US$ 1.91 billion in 2022 and is expected to register a revenue CAGR of 10.25% to reach US$ 4.61 billion by 2031.
Antisense Oligonucleotides Market Fundamentals
Antisense oligonucleotides (ASOs) regulate inappropriate gene expression in pathological situations by specifically inhibiting the production of their mRNA targets. Antisense oligonucleotide technologies operate on the assumption that blocking mRNA activity might selectively inhibit the production of undesired genes. The technique has been useful for the research and development of drugs.
ASOs are classified into two major subtypes: RNase H competent and steric block. The endogenous RNase H enzyme RNASEH1 detects and catalyzes the degradation of RNA-DNA heteroduplex substrates generated when DNA-based oligonucleotides bind to their respective mRNA transcripts. In recent years, antisense oligonucleotide technologies have been widely exploited as potent and promising tools for drug development. The number of antisense compounds advancing through clinical studies is also increasing. Moreover, the technologies are projected to become a reality in the upcoming years, providing an easy and efficient drug discovery and development method. Furthermore, the technique has been proven to be an effective therapeutic agent and crucial molecular biology reagent. ASOs are employed to develop mRNA selective knockouts in both in vitro and in vivo processes. ASOs may selectively target genes, especially those that are challenging to target with small molecule inhibitors or neutralizing antibodies; therefore, they can be employed for many treatments.
[9769868]
Antisense Oligonucleotides Market Dynamics
The increasing application of ASOs in research, genetic testing, and forensics is the major factor in fueling the revenue growth of the antisense oligonucleotides market. This is due to their ability to target and modify gene expression. This technology can be used to modulate the expression of specific genes, allowing researchers to understand gene function and regulation better. ASOs are also used to modulate gene expression in various diseases, such as cancer, infectious diseases, and genetic disorders, providing researchers with a powerful means to identify novel therapeutic targets. Furthermore, ASOs can be used to validate hypotheses and provide a better understanding of the underlying biology of diseases, making them a valuable asset in drug discovery and development.
Increasing advancements in ASOs are expected to augment the antisense oligonucleotides market revenue growth. For instance, researchers predicted that ASOs are a novel and extremely promising class of medicines for customized treatment. In the last decade, important chemical advances and enhancements to the foundation of ASOs have converted them into authorized and marketable pharmaceuticals.
The global antisense oligonucleotides market is also growing as several market players are showing interest in developing therapeutics based on ASOs. For instance, Bio-Path Holdings, Inc. is researching its potential antisense oligonucleotide-based drug, BP10002 (Liposomal Bcl-2). It is a neutral-charge, liposome-incorporated antisense medication intended to prevent programmed cell death by inhibiting the protein production of Bcl-2.
However, ASOs often degrade before accessing the target, reducing the treatment viability and impeding market revenue growth. Moreover, ASO products are subject to several stringent regulations and standards enforced by regulatory bodies, which is anticipated to slow down market revenue growth.
Antisense Oligonucleotides Market Ecosystem
The global antisense oligonucleotides market has been analyzed from four perspectives: drug, indications, end user, and region.
Antisense Oligonucleotides Market by Drug
[56889]
Based on the drug, the global antisense oligonucleotides market has been segmented into fomivirsen, mipomersen, nusinersen, patisiran, inotersen, eteplirsen, and others.
The nusineren segment accounts for a prominent position in the global antisense oligonucleotides market. Nusinersen, used to treat spinal muscular atrophy, is one of the most popular ASO drugs. It improves the synthesis of a survival motor neuron protein required for proper motor neuron growth and function. Eteplirsen is another potential antisense oligonucleotide drug that recently gained traction for its efficacy in treating Duchenne muscular dystrophy. The drug bypasses a particular exon in the gene that makes the dystrophin protein, which is essential for the healthy operation of muscles.
Antisense Oligonucleotides Market by Indication
Based on indication, the global antisense oligonucleotides market has been segmented into ocular disease, diabetes, cancer, spinal muscular atrophy, and other indications.
The spinal muscular atrophy segment dominates the market with the largest revenue share. Studies have demonstrated that ASOs can improve motor function, strength, and endurance in patients with spinal muscular dystrophy by targeting the abnormal gene responsible for the condition. Additionally, these oligonucleotides are well-tolerated with minimal side effects. They may also decrease muscle damage and delay the progression of spinal muscular dystrophy. This treatment could provide a long-term, effective approach to treating this debilitating condition.
Antisense Oligonucleotides Market by End User
Based on end user, the global antisense oligonucleotides market has been segmented into basic research, target validations, and genomics.
The basic research segment accounts for the majority of the market revenue share. ASOs are mostly used in basic research as they can be used to investigate gene function and identify molecular targets for drug discovery. ASOs can also be used to study the effects of gene expression changes due to mutations or other genetic alterations. In addition, ASOs are utilized to generate animal disease models and characterize gene regulatory pathways. Due to their specificity and relatively low toxicity, ASOs have become increasingly popular in basic research.
Antisense Oligonucleotides Market by Region
Based on region, the global antisense oligonucleotides market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
North America dominates the global antisense oligonucleotides market, owing to advanced healthcare infrastructure and increased spending on research. Additionally, the usage of ASOs in treating various diseases, such as cancer and neurological disorders, is growing rapidly. The increasing prevalence of life-threatening diseases and the growing need for personalized medicine in the region are potential driving factors increasing the demand for these therapeutics. Furthermore, growth in the research and development initiatives by pharmaceutical companies, supportive government policies, and raised venture capital investments are providing further impetus to the revenue growth of the North America antisense oligonucleotides market.
The Europe antisense oligonucleotides market is characterized by the rising demand for ASOs in the research and development of many new drugs. Moreover, top players are merging and collaborating with players in this region to introduce new and innovative antisense oligonucleotide-based products.
Asia Pacific is anticipated to grow with high revenue CAGR during the forecast period. This is attributed to increasing investments in biotech research, growing demand for personalized medicine, and a favorable regulatory environment. Additionally, personalized medicine is gaining ground in Asia Pacific, as academics and healthcare professionals are gaining advanced knowledge about the efficacy of custom-tailored therapies for better patient outcomes. ASOs are appropriate for this strategy because they may be tailored to particular requirements.
Antisense Oligonucleotides Market Competitive Landscape
The prominent players in the global antisense oligonucleotides market include:
Leading players are progressively focused on implementing strategies, such as adopting modern technologies, product advancements, mergers and acquisitions, joint ventures, alliances, and partnerships, to strengthen their market positions in the antisense oligonucleotide market. Product launches, approvals, and promising product pipelines provide new growth avenues in the market. However, loss of market exclusivity for patented products, intense generic competition, and tightening regulations could affect business operations.
Antisense Oligonucleotides Market Strategic Developments
The high adoption of ASOs in personalized medicines, and their high usage in research and development, are supporting the market revenue growth of the global antisense oligonucleotides market.
Some prominent market players in the global antisense oligonucleotides market include Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Biogen, Inc., and Alny.
The spinal muscular atrophy segment is anticipated to grow rapidly during the forecast period.
Asia Pacific is expected to mark the highest revenue growth during the forecast period from 2023 to 2031.
Antisense oligonucleotide products are subject to several stringent regulations and standards enforced by regulatory bodies, which are anticipated to slow down market development.
*Insights on financial performance are subject to the availability of information in the public domain